Multiple Myeloma an incurable disease, but I have spent the last 25 years in remission using a blend of conventional oncology and evidence-based nutrition, supplementation, and lifestyle therapies from peer-reviewed studies that your oncologist probably hasn't told you about.
Click the orange button to the right to learn more about what you can start doing today.
Multiple myeloma chemotherapy has changed a lot since I was first diagnosed. Well, chemotherapy hasn’t changed. But the FDA has approved many more chemo combinations and MM patients and survivors have many more chemo regimens in 2019 than when I was diagnosed in 1994.
Click here to read my Multiple Myeloma history. I made a lot of mistakes in the first years of my cancer battle. My mantra is that I wish I knew then what I know now. Below you will find a list of the different chemotherapy options for Multiple Myeloma.
I have good news and bad news. The bad news is that conventional oncology considers MM to be incurable. If you follow the therapies offered by your oncologist exclusively you will reach remission and relapse repeatedly and your quality-of-life will decline until you are told that nothing more can be done for you.
According to the American Cancer Society, the average life expectancy of a newly diagnosed MMer is 5-7 years. The five-year survival rate for MM is less than 47%.
The good news is that the number of chemotherapies for the treatment of MM has increased significantly since I was first diagnosed in February of 1994. There are more than 17 FDA approved chemotherapies available for your treatment today. Further, there are many evidence-based, non-toxic MM therapies.
All chemotherapies have short, long-term and late stage side effects. I’m not only talking about those side effects that we are all familiar with such as hair loss and nausea. I’m talking about nerve, heart and brain damage.
My experience and research makes is clear that the key to achieving the longest, deepest and most side-effect free series of remissions is to use the best of both conventional (FDA approved) and experienced-based, non-conventional therapies.
If you or a loved one have been diagnosed with Multiple Myeloma, let me say this loud and clear:
It is critical that you become an active participant in your care. Learn everything you can.
I am alive today largely because I took the time to find out everything I could about Multiple Myeloma and sought out the full spectrum of evidence-based MM therapies both conventional (FDA approved) and non-conventional.
Please watch the video below to learn more about the evidence-based, integrative therapies to combat treatment side effects and enhance your chemotherapy.
Here is the list of the treatment regimens currently offered to Multiple Myeloma patients:
Have you been diagnosed with multiple myeloma? Are you considering induction therapy and or an autologous stem cell transplant? Are you experiencing any symptoms such as bone pain, fatigue and or kidney damage?
If you would like to ask me a question or make a comment, please leave a comment and I will reply ASAP.
“The past decade has seen significant advances in our understanding and treatment of multiple myeloma (MM) and its precursor diseases. These advances include gains in knowledge of the underlying pathobiology including molecular and cellular prognostic factors for disease progression.
In parallel we have witnessed the availability of novel therapeutics. Together these advances have translated into improvements in long-term clinical benefit and survival in MM.
Indeed, it has been shown that patients diagnosed in the last decade have experienced almost doubling of median survival time.1 This manuscript aims to review and give further insight into drug development and novel drug approvals that have revolutionized the treatment of MM.
After half a century of treatments that conferred only modest benefit at the expense of toxicity the last decade has brought the rapid development of novel therapies and the development of laboratory techniques that have uncovered a deeper understanding of myeloma biology.
An important development has been the ability to detect minimal residual disease (MRD) with greater sensitivity using both multi-color flow cytometry and next generation sequencing.
This has been important because newer therapies have achieved higher response rates that in many instances have been “deeper” in nature.2 With the importance of MRD as a marker of long-term clinical benefit established by two independent groups3,4 the International Myeloma Working Group (IMWG) recently revised the MM response criteria by adding “MRD negativity” as a deeper and more stringent response than stringent complete response.5
These advances have contributed to the longer overall survival (OS) of patients diagnosed with MM in the past decade and an expectation of further improvement in the coming decade with rapid approval of drugs by the US Food and Drug administration (FDA) and the European Medicines Agency (EMA).